Cargando…

Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study

BACKGROUND: Brazil and Scotland have used mRNA boosters in their respective populations since September 2021, with Omicron’s emergence accelerating their booster program. Despite this, both countries have reported substantial recent increases in Coronavirus Disease 2019 (COVID-19) cases. The duratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerqueira-Silva, Thiago, Shah, Syed Ahmar, Robertson, Chris, Sanchez, Mauro, Katikireddi, Srinivasa Vittal, de Araujo Oliveira, Vinicius, Paixão, Enny S., Rudan, Igor, Junior, Juracy Bertoldo, Penna, Gerson O., Pearce, Neil, Werneck, Guilherme Loureiro, Barreto, Mauricio L., Boaventura, Viviane S., Sheikh, Aziz, Barral-Netto, Manoel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879484/ https://www.ncbi.nlm.nih.gov/pubmed/36630477 http://dx.doi.org/10.1371/journal.pmed.1004156

Ejemplares similares

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
por: Katikireddi, Srinivasa Vittal, et al.
Publicado: (2022)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
por: Simpson, Colin R., et al.
Publicado: (2022)

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
por: Florentino, Pilar T V, et al.
Publicado: (2022)

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
por: Paixao, Enny S., et al.
Publicado: (2022)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Vaccination plus previous infection: protection during the omicron wave in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era
por: Shah, Syed Ahmar, et al.
Publicado: (2022)

Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
por: Florentino, Pilar T. V., et al.
Publicado: (2022)

Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study
por: Pescarini, Julia M., et al.
Publicado: (2023)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2021)

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
por: Simpson, C. R., et al.
Publicado: (2021)

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
por: Agrawal, Utkarsh, et al.
Publicado: (2021)

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
por: Rudan, Igor, et al.
Publicado: (2022)

Understanding the Development of Minimum Unit Pricing of Alcohol in Scotland: A Qualitative Study of the Policy Process
por: Katikireddi, Srinivasa Vittal, et al.
Publicado: (2014)

Uptake, effectiveness and safety of COVID-19 vaccines in children and young people in Scotland: Protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II)
por: Adeloye, Davies, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Implementing a Public Health Objective for Alcohol Premises Licensing in Scotland: A Qualitative Study of Strategies, Values, and Perceptions of Evidence
por: Fitzgerald, Niamh, et al.
Publicado: (2017)

The health impact of Scotland's Baby Box Scheme: a natural experiment evaluation using national linked health data
por: McCabe, Ronan, et al.
Publicado: (2023)

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment
por: Rudan, Igor, et al.
Publicado: (2021)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023)

How do trends in mortality inequalities by deprivation and education in Scotland and England & Wales compare? A repeat cross-sectional study
por: McCartney, Gerry, et al.
Publicado: (2017)

Impact on emergency and elective hospital-based care in Scotland over the first 12 months of the pandemic: interrupted time-series analysis of national lockdowns
por: Shah, Syed Ahmar, et al.
Publicado: (2022)

Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study
por: Shi, Ting, et al.
Publicado: (2022)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
por: Xie, Junqing, et al.
Publicado: (2022)

Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
por: Hasan, Amal, et al.
Publicado: (2022)

Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
por: Alfaleh, Amjad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d5ci5tl8jcpq41tk6pqu679dd6